Enfuvirtide: A fusion inhibitor for the treatment of HIV infection

Clinical Therapeutics

Volumn 26, Issue 3, 2004, Pages 352-378

  Fung, Horatio B ^a   Guo, Yi ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Enfuvirtide; Fusion inhibitor; HIV infection; T 20

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; AMPRENAVIR; AMYLASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; EFAVIRENZ; ENFUVIRTIDE; GAMMA GLUTAMYLTRANSFERASE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; VIRUS RNA;

ABDOMINAL PAIN; ABSCESS; ADOLESCENT; ADULT; AGED; ANEMIA; ANIMAL EXPERIMENT; ANOREXIA; ASTHENIA; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DERMATITIS; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; ECCHYMOSIS; EOSINOPHILIA; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLATULENCE; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPOTENSION; IMMUNE COMPLEX DISEASE; INJECTION PAIN; INSOMNIA; KIDNEY FAILURE; LIMB PAIN; LIVER DYSFUNCTION; LIVER FAILURE; LYMPHADENITIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MEDLINE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MULTICENTER STUDY; NAUSEA; NONHUMAN; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRESCHOOL CHILD; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RAT; RESPIRATORY DISTRESS; REVIEW; SCHOOL CHILD; SIDE EFFECT; SKIN BLEEDING; SKIN CYST; SKIN DISCOLORATION; SKIN EDEMA; SKIN INDURATION; SLEEP DISORDER; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VIRUS CELL INTERACTION; VOMITING; WEIGHT REDUCTION;

EID: 1842502994     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90032-X     Document Type: Article

References (77)

1. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA. AIDS. 1997;11:F101-F105.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
3. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents - July 14, 2003. Available at: http://www.aidsinfo.nih.gov/ guidelines/ adult/archive/AA_071403.pdf. Accessed October 31, 2003.
4. Streicher HZ, Reitz MS Jr, Gallo RC. Human immunodeficiency viruses. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, Pa: Churchill Livingstone; 2000:1874-1887.
5. Estimated persons living with AIDS, by region of residence and year, 1993 through 2001, United States. Available at: http://www.cdc.gov/hiv/stats/ hasr1302/ table28.htm. Accessed October 31, 2003.
6. Gulick RM. New antiretroviral drugs. Clin Microbiol Infect. 2003;9:186-193.
7. Coleman CI, Musial BL, Ross J. Enfuvirtide: The first fusion inhibitor for the treatment of patients with HIV-1 infection. Formulary. 2003;38:204-222.
8. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
9. Holmberg SD, Hamburger ME, Moorman AC, et al, for the HIV Outpatient Study Investigators. Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression. Clin Infect Dis. 2003;37:702-707.
10. Fikkert V, Cherepanov P, Van Laethem K, et al. env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors. Antimicrob Agents Chemother. 2002;46:3954-3962.
11. De Clercq E. Novel compounds in preclinical/early clinical development for the treatment of HIV infections [published correction appears in Rev Med Virol. 2000;10:349]. Rev Med Virol. 2000;10:255-277.
12. Nagashima KA, Thompson DA, Rosenfield SI, et al. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis. 2001;183:1121-1125.
13. De Clercq E. New anti-HIV agents and targets. Med Res Rev. 2002;22:531-565.
14. FDA approves first drug in new class of HIV treatments for HIV infected adults and children with advanced disease [press release]. Available at: http://www.fda. gov/bbs/topics/NEWS/2003/NEW00879.html. Accessed October 31, 2003.
15. Fuzeon [package insert]. Durham, NC, and Nutley, NJ: Trimeris, Inc, and Roche Laboratories Inc; 2003.
16. Moore JP, Doms RW. The entry of entry inhibitors: A fusion of science and medicine. Proc Natl Acad Sci USA. 2003;100:10598-10602.
17. Reeves JD, Gallo SA, Ahmad N, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/ coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci USA. 2002;99:16249-16254.
18. Cooley LA, Lewin SR. HIV-1 cell entry and advances in viral entry inhibitor therapy. J Clin Virol. 2003;26:121-132.
19. Cammack N. The potential for HIV fusion inhibition. Curr Opin Infect Dis. 2001;14:13-16.
20. Chen RY, Kilby JM, Saag MS. Enfuvirtide. Expert Opin Investig Drugs. 2002;11:1837-1843.
21. Xu Y, Zhang X, Matsuoka M, Hattori T. The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41. FEBS Lett. 2000; 487:185-188.
22. Doms RW, Trono D. The plasma membrane as a combat zone in the HIV battlefield. Genes Dev. 2000;14:2677-2688.
23. Montaner J, Mellors J. Meeting report from the 2nd International HIV Workshop on management of treatment-experienced patients. September 26-27, 2002, San Diego, Calif, USA. Antivir Ther. 2002;7(Suppl 2):S217-S233.
24. Ketas TJ, Klasse PJ, Spenlehauer C, et al. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. AIDS Res Hum Retroviruses. 2003;19:177-186.
25. Center for Drug Evaluation and Research. Application number 21-481. Microbiological review(s). Available at: http://www.fda.gov/cder/foi/nda/2003/ 21481_Fuzeon_ Microbr.pdf. Accessed October 31, 2003.
26. Lambert DM, Johnson MR, Black PL, et al. Antiviral activity and pharmacokinetics of T-20, an amphipathic helical peptide derived from gp41. In: Program and Abstracts of the VIIIth International AIDS Conference; July 7-12, 1996; Vancouver, British Columbia, Canada. Faribault, Minn: Marathon Multimedia; 1996. Abstract MoA1080.
27. Hopkins S, Lambert DM, Recny MR, et al. Pentafuside (T-20), a novel inhibitor of HIV-1 fusion: Pharmacokinetics in rodents, monkeys and man. Available at: http://www.retroconference.org/retrovirus97/abstracts/ a779_abstract.htm. Accessed February 19, 2004.
28. Clinical pharmacology biopharmaceutics review(s). Drug review package, Fuzeon (enfuvirtide) for injection. Company: Hoffman-LaRoche, Inc. Application no.: 021481. Approval date: 3/13/2003. Available at: http://www.fda.gov/cder/ foi/nda/2003/021481_fuzeon_ review.htm. Accessed October 31, 2003.
29. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med. 1998;4:1302-1307.
30. Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults [published correction appears in AIDS Res Hum Retroviruses. 2003;19:83]. AIDS Res Hum Retroviruses. 2002;18:685-693.
31. Lalezari JP, Eron JJ, Carlson M, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS. 2003;17:691-698.
32. Zhang X, Nieforth K, Lang JM, et al. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther. 2003;72:10-19.
33. Lalezari JP, Patel IH, Zhang X, et al. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. J Clin Virol. 2003;28:217-222.
34. Church JA, Cunningham C, Hughes M, et al, for the PACTG P1005 Study Team. Pediatric AIDS Clinical Trial Group. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr Infect Dis J. 2002;21:653-659.
35. Soy D, Aweeka FT, Church JA, et al, for Pediatric AIDS Clinical Trial Group (PACTG) Study P1005 Investigators. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: Searching for exposure-response relationships. Clin Pharmacol Ther. 2003;74:569-580.
36. Bellibas SE, Siddique Z, Dorr A, et al, for the T20-310/NV16056 Study Group. Pharmacokinetics of enfuvirtide in pediatric HIV-infected patients receiving combination therapy. Antivir Ther. 2003;8(Suppl 1):S421. Abstract 841.
37. Roman F, Gonzalez D, Boulme R, et al. No evidence of primary resistance to T-20 in treatment-naive patients infected with non-B HIV-1 isolates. In: Program and Abstracts of the XIVth International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Faribault, Minn: Marathon Multimedia; 2002. Abstract MoPeA3026.
38. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol. 1998;72:986-993.
39. Xu L, Hué S, Taylor S, et al. Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients. AIDS. 2002;16:1684-1686.
40. Villahermosa ML, Perez-Alvarez L, Carmona R, et al. Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of HIV-1 non-B subtypes and recombinants. AIDS. 2003;17:1083-1086.
41. Zollner B, Feucht HH, Schroter M, et al. Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients. AIDS. 2001;15:935-936.
42. Cuevas MT, Villahermosa ML, Carmona R, et al. HIV-1 gp41 variability in a cohort of Spanish patients. In: Program and Abstracts of the XIVth International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Faribault, Minn: Marathon Multimedia; 2002. Abstract MoPeA3024.
43. Hanna SL, Yang C, Owen SM, Lal RB. Variability of critical epitopes within HIV-1 heptad repeat domains for selected entry inhibitors in HIV-infected populations worldwide [published correction appears in AIDS. 2002;16:1847]. AIDS. 2002;16:1603-1608.
44. Roman F, Gonzalez D, Lambert C, et al. Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr. 2003;33:134-139.
45. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46:1896-1905.
46. Greenberg ML, Melby T, Sista P, et al. Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 to 24 weeks. Available at: http://www. retroconference.org/2003/Abstract/Abstract.aspx? AbstractID=1687. Accessed February 19, 2004.
47. Tremblay CL, Kollmann C, Giguel F, et al. In vitro synergy observed between the fusion inhibitor T-20 and a CCR5 inhibitor TAK-779. In: Abstracts: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy [CD-ROM]. Washington, DC: American Society for Microbiology; 2000. Abstracts 34704.
48. Olson WC, Nagashima KA, Rosenfield S, Maddon PJ. Potent synergistic inhibition of HIV-1 by combinations of the viral entry inhibitors PRO 542 and T-20. In: Abstracts: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy [CD-ROM]. Washington, DC: American Society for Microbiology; 2000. Abstract 33368.
49. Barney S, Guthrie K, Davis D, et al. Pentafuside (T-20), a novel inhibitor of HIV-1 fusion and infection, is synergistic when used in combination with reverse transcriptase and protease inhibitors in vitro. Antiviral Res. 1998;37:A54.
50. Lalezari J, DeJesus E, Northfelt G, et al. A week-48 assessment of a randomized, controlled, open-label phase II trial (T20-206) evaluating 3 doses of T-20 in PI-experienced, NNRTI-naive patients infected with HIV-1. Available at: http://www.retroconference.org// 2002/Abstract/13592.htm. Accessed February 19, 2004.
51. Clinical review. Drug review package, Fuzeon (enfuvirtide) for injection. Company: Hoffman-LaRoche, Inc. Application no.: 021481. Approval date: 3/13/2003. Available at: http://www.fda.gov/cder/foi/nda/2003/ 021481_fuzeon_review.htm. Accessed October 31, 2003.
52. Lalezari JP, Henry K, O'Hearn M, et al, for the TORO 1 Study Group. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America [published correction appears in N Engl J Med. 2003;349:1100]. N Engl J Med. 2003;348:2175-2185.
53. Lazzarin A, Clotet B, Cooper D, et al, for the TORO 2 Study Group. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-2195.
54. Delfraissy J-F, Montaner J, Eron J, et al, for the TORO Study Team. Summary of pooled efficacy and safety analyses of enfuvirtide (ENF) treatment for 24 weeks in TORO 1 and TORO 2 phase III trials in highly antiretroviral (ARV) treatment-experienced patients. Available at: http://www.retroconference. org/Archive/ Posters/Retro10/568.pdf. Accessed February 19, 2004.
55. Battegay M, DeMasi R, Delehanty J, et al, for the TORO 1 and TORO 2 Study Groups. Antivir Ther. 2003;8(Suppl 1):S340. Abstract 574.
56. Hornberger J, Green J. Clinical prognosis of enfuvirtide in combination with an optimized background regimen among categories of baseline CD4 cell count and HIV antiretroviral resistance. Antivir Ther. 2003;8(Suppl 1):S310. Abstract 478.
57. Trottier B, Arasteh K, Henry K, et al, for the TORO Study Team. Durability of response to enfuvirtide through 48 weeks in the TORO trials. In: Abstracts: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy [CD-ROM]. Washington, DC: American Society for Microbiology; 2003. Abstract H-835.
58. Eron J, Delfraissy JF, Kuritzkes D, et al, for the TORO Study Team. Safety of enfuvirtide through 48 weeks of therapy in the TORO trials. In: Abstracts: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy [CD-ROM]. Washington, DC: American Society for Microbiology; 2003. Abstract H-836.
59. Walmsley S, Henry K, Katlama C, et al. Lack of influence of gp41 antibodies that cross-react with enfuvirtide on the efficacy and safety of enfuvirtide in TORO 1 and TORO 2 phase III trials. Available at: http://www.retroconference.org/2003/Abstract/Abstract. aspx?AbstractID=1463. Accessed February 19, 2004.
60. Glutzer E. Treatment with a new fusion inhibitor: Patient issues with enfuvirtide (T-20). A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002. AIDS Read. 2003;13(Suppl 3):S14-S16.
61. Myers SA, Selim A, McDaniel M, et al. A prospective clinical and histological examination of injection sites with the HIV fusion inhibitor enfuvirtide. In: Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL. Abstract H-2015.
62. Ball RA, Kinchelow T, for the ISR Substudy Group. Pathology of injection site reactions with enfuvirtide (T-20). Available at: http://www. retroconference.org/ Archive/Posters/Retro10/714.pdf. Accessed February 19, 2004.
63. Boyd M, Ruxrungtham K, Zhang X, et al. Enfuvirtide: Investigations on the drug interaction potential in HIV-infected patients. Available at: http://www.retroconference.org/2003/Abstract/Abstract.aspx?AbstractID=93. Accessed February 19, 2004.
64. Steinbrook R. HIV infection - A new drug and new costs. N Engl J Med. 2003;348:2171-2172.
65. Reddy D. David Reddy - taking HIV therapy to new frontier (interviewed by Pam Das). Lancet Infect Dis. 2003;3:110-113.
66. 2003 Drug Topics Red Book. Montvale, NJ: Medical Economics; 2003.
67. Cohen CJ, Clumeck N, Molina JM, et al. Impact of enfuvirtide on health-related quality of life. Antivir Ther. 2003;8(Suppl 1):S510. Abstract 1148.
68. Hornberger JC, Witek J, Kilby JM, et al. Clinical prognosis and cost-effectiveness of enfuvirtide in the United States. In: Abstracts: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy [CD-ROM]. Washington, DC: American Society for Microbiology; 2003. Abstract H-837.
69. Fletcher CV. Enfuvirtide, a new drug for HIV infection. Lancet. 2003;361:1577-1578.
70. Tashima KT, Carpenter CC. Fusion inhibition - a major but costly step forward in the treatment of HIV-1. N Engl J Med. 2003;348:2249-2250.
71. Stocker H, Scheller C, Jassoy C. Destruction of primary CD4+ T cells by cell-cell interaction in human immunodeficiency virus type 1 infection in vitro. J Gen Virol. 2000;81:1907-1911.
72. Richman DD. Nailing down another HIV target. Nat Med. 1998;4:1232-1233.
73. Cohen CJ, Dusek A, Green J, et al. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: Patient satisfaction and impact on activities of daily living. AIDS Patient Care STDs. 2002;16:327-335.
74. Cohen C, Hellinger J, Johnson M, et al. Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks. HIV Clin Trials. 2003;4:347-357.
75. Bray BL. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev. 2003;2:587-593.
76. Fuzeon Progressive Distribution Program. Fuzeon Web site. Available at: http://www.fuzeon.com/1000/1600. asp?nav=pdp. Accessed February 18, 2004.
77. Sax PE. Report from the Tenth Retrovirus Conference. New drugs. AIDS Clin Care. 2003;15:32-33.